Abeona Therapeutics Operating Income 2010-2022 | ABEO

Abeona Therapeutics operating income from 2010 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Abeona Therapeutics Annual Operating Income
(Millions of US $)
2021 $-90
2020 $-81
2019 $-77
2018 $-58
2017 $-28
2016 $-24
2015 $-19
2014 $-3
2013 $-4
2012 $-4
2011 $-8
2010 $-8
2009 $-10
Abeona Therapeutics Quarterly Operating Income
(Millions of US $)
2022-03-31 $-21
2021-12-31 $-50
2021-09-30 $-15
2021-06-30 $-14
2021-03-31 $-15
2020-12-31 $-14
2020-09-30 $-6
2020-06-30 $-12
2020-03-31 $-48
2019-12-31 $-16
2019-09-30 $-18
2019-06-30 $-24
2019-03-31 $-19
2018-12-31 $-18
2018-09-30 $-17
2018-06-30 $-13
2018-03-31 $-11
2017-12-31 $-9
2017-09-30 $-5
2017-06-30 $-8
2017-03-31 $-5
2016-12-31 $-6
2016-09-30 $-5
2016-06-30 $-7
2016-03-31 $-6
2015-12-31 $-6
2015-09-30 $-6
2015-06-30 $-4
2015-03-31 $-2
2014-12-31 $-0
2014-09-30 $-1
2014-06-30 $-1
2014-03-31 $-1
2013-12-31 $-1
2013-09-30 $-1
2013-06-30 $-2
2013-03-31 $-1
2012-12-31 $-1
2012-09-30 $-1
2012-06-30 $-1
2012-03-31 $-1
2011-12-31 $-2
2011-09-30 $-2
2011-06-30 $-2
2011-03-31 $-2
2010-12-31 $-2
2010-09-30 $-2
2010-06-30 $-2
2010-03-31 $-2
2009-12-31 $-2
2009-09-30 $-4
2009-06-30 $-2
2009-03-31 $-2
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.022B $0.003B
Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00